KLF2增强子变异rs4808485通过调节炎症小体机制和细胞稳态增加狼疮风险
该研究旨在确定KLF2位点中与系统性红斑狼疮(SLE)易感性相关的因果功能变异、靶基因及遗传机制。通过生物信息学优先筛选变异,并利用荧光素酶报告基因、染色质免疫沉淀、染色体构象捕获及CRISPR基因编辑等技术验证rs4808485的功能。结果显示rs4808485位于活性染色质增强子区,等位基因差异影响增强子活性和转录因子结合,并与KLF2启动子存在长距离染色质相互作用。删除Jurkat细胞中该增强子可破坏NLRP3炎症小体机制,降低KLF2并升高CASPASE1、IL-1β和GSDMD水平,同时促进细胞增殖和细胞周期进展。
要点
- rs4808485位于KLF2增强子区,等位基因差异影响增强子活性和组蛋白修饰、Pol II、CTCF、P300、PARP1结合。
- 染色体构象捕获显示rs4808485与KLF2启动子存在长距离染色质相互作用,并经CRISPR编辑验证。
- Jurkat细胞中删除rs4808485增强子导致KLF2降低、CASPASE1/IL-1β/GSDMD升高,并促进增殖和细胞周期进展。
核心结论
- rs4808485通过调节KLF2表达来调控炎症小体和细胞稳态,从而建立该变异与SLE易感性之间的机制联系。
研究设计与样本
- 研究采用生物信息学方法优先筛选可能的功能变异,并用多种实验技术(包括基因组编辑)验证最佳候选变异。
- 基因表达在健康对照(HCs)与伴或不伴狼疮肾炎的SLE患者(LN+、LN-)之间进行比较。
主要发现
- 荧光素酶报告基因检测和染色质免疫沉淀-qPCR显示rs4808485等位基因差异影响增强子活性及活性组蛋白标记(H3K27ac、H3K4me3、H3K4me1)、Pol II、CTCF、P300和转录因子PARP1的结合。
- 染色体构象捕获-qPCR揭示rs4808485与KLF2启动子之间的长距离染色质相互作用,并经基于CRISPR的遗传和表观遗传编辑在Jurkat和淋巴母细胞样细胞中直接验证。
- 在Jurkat细胞中删除rs4808485增强子(KO)通过降低KLF2并升高CASPASE1、IL-1β和GSDMD水平破坏NLRP3炎症小体机制。
- 敲除细胞较野生型表现出更高的增殖和细胞周期进展。
- RNA-seq在HC、LN+和LN-中验证了KLF2与炎症小体机制之间的相互作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: A recent genome-wide association study linked KLF2 as a novel Asian-specific locus for systemic lupus erythematosus (SLE) susceptibility. However, the underlying causal functional variant(s), cognate target gene(s) and genetic mechanisms associated with SLE risk are unknown. METHODS: We used bioinformatics to prioritise likely functional variants and validated the best candidate with diverse experimental techniques, including genome editing. Gene expression was compared between healthy controls (HCs) and patients with SLE with or without lupus nephritis (LN+, LN-). RESULTS: Through bioinformatics and expression quantitative trait locus analyses, we prioritised rs4808485 in active chromatin, predicted to modulate KLF2 expression. Luciferase reporter assays and chromatin immunoprecipitation-qPCR demonstrated differential allele-specific enhancer activity and binding of active histone marks (H3K27ac, H3K4me3 and H3K4me1), Pol II, CTCF, P300 and the transcription factor PARP1. Chromosome conformation capture-qPCR revealed long-range chromatin interactions between rs4808485 and the KLF2 promoter. These were directly validated by CRISPR-based genetic and epigenetic editing in Jurkat and lymphoblastoid cells. Deleting the rs4808485 enhancer in Jurkat (KO) cells disrupted NLRP3 inflammasome machinery by reducing KLF2 and increasing CASPASE1, IL-1β and GSDMD levels. Knockout cells also exhibited higher proliferation and cell-cycle progression than wild type. RNA-seq validated interplay between KLF2 and inflammasome machinery in HC, LN+ and LN-. CONCLUSIONS: We demonstrate how rs4808485 modulates the inflammasome and cellular homoeostasis through regulating KLF2 expression. This establishes mechanistic connections between rs4808485 and SLE susceptibility.
引用
- Singh MK, Rallabandi HR, Zhou XJ, et al. KLF2 enhancer variant rs4808485 increases lupus risk by modulating inflammasome machinery and cellular homoeostasis. Ann Rheum Dis. 2024. PMID: 38373841. doi:10.1136/ard-2023-224953
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。